>All Other Proteins
>Human Glypican 3 / GPC3 Protein, Fc Tag, low endotoxin
This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 87.4 kDa. GP3-H5258 may be cleaved into secrete GPC3, short propeptide (aa 483-559 predicted) & Fc tag, long propeptide (aa 359-559 predicted) & Fc tag. The protein migrates as 100 kDa (secrete GPC3 & propeptide & Fc tag), 58 kDa (long propeptide & Fc tag), and 40 kDa (short propeptide & Fc tag) on a SDS-PAGE gel under reducing (R) condition.
>90% GPC3 and 2-8% human IgG1 Fc fragment as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
Human Glypican 3, Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
293 cells were transfected with anti-GPC3-scFv and RFP tag. 2e5 of the cells were first stained with B. Human Glypican 3, Fc Tag, low endotoxin (Cat. No. GP3-H5258, 3 μg/ml) and C. human Fc tag protein control, followed by FITC-conjugated anti-human IgG Fc antibody. A. Non-transfected 293 cells and C. human Fc tag protein control were used as negative control. RFP was used to evaluate CAR (anti-GPC3-scFv) expression and FITC was used to evaluate the binding activity of Human Glypican 3, Fc Tag, low endotoxin (Cat. No. GP3-H5258).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $300.00
Price(USD) : $1980.00
This web search service is supported by Google Inc.